Human Liver Models Market by Drug Discovery Platform (Non-alcoholic Fatty Liver Organoids, Liver-on-a-chip, 2D Models, Animal Models, 3D Bioprinting), and Region (North America, Europe, Asia Pacific, Rest of the World) - Global Forecast to 2022
|出版日期||內容資訊||英文 39 Pages
|人類肝臟模型世界市場∼2022年：創藥平台 (非酒精系脂肪性肝病患、肝臟機能晶片、2D模型、動物模型、生物3D列印)、地區分類預測 Human Liver Models Market by Drug Discovery Platform (Non-alcoholic Fatty Liver Organoids, Liver-on-a-chip, 2D Models, Animal Models, 3D Bioprinting), and Region (North America, Europe, Asia Pacific, Rest of the World) - Global Forecast to 2022|
|出版日期: 2018年04月26日||內容資訊: 英文 39 Pages||
世界人類肝臟模型市場2017年達13億5000萬美元、預計2022年可達25億6000萬美元、13.6%CAGR (年複合成長率) 成長。其中肝臟機能晶片 (Liver-on-a-chip) 最被期待今後可大幅成長。地區分類市場成長率比較、北美各國最高。市場成長主因是研究資金與創投增加、肝臟類器官相關研究活絡、(為了讓治療失敗損失最小化) 藥物毒性早期發現的必要性等。
The global human liver models market is expected to reach USD 2.56 billion by 2022 from USD 1.35 billion in 2017, at a CAGR of 13.6%. Growing focus on developing alternatives for animal testing models, significant increase in research funding and venture capital investments for the development of liver models, growing initiatives to increase awareness about liver organoids, increasing research activities on liver organoids, increasing prevalence of non-alcoholic fatty liver disease, and growing need for the early detection of drug toxicity to minimize financial losses due to late-stage drug failure are expected to drive the growth of the human liver models market. However, issues related to the incorporation of organoids into existing workflows are expected to restrain the growth of this market to a certain extent.
Based on type, the market is segmented into liver organoids, liver-on-a-chip, 2D models, animal models, and 3D bioprinting. The liver-on-a-chip segment is expected to grow at the highest CAGR during the forecast period. This can be attributed to the simplicity of this model and the ability of on-chip hepatic tissues to maintain metabolic activity and phenotype similar to that of the in vivo environment. Moreover, the majority of the key players, research institutes, and government and non-government organizations are raising funds for the development of innovative liver-based models. In addition, key players operating in this market are entering into partnerships and collaborations with pharmaceutical companies to strengthen their market position. This strategy is enabling market players to evaluate the performance of their livers-on-a-chip offerings in drug development and other pharmaceutical research processes. Such funding initiatives from the government and private investors are expected to provide an impetus to market growth.
North America is expected to witness the highest growth during 2017 to 2022, owing to well-established pharmaceutical and biotechnology industry and increasing government spending. Furthermore, growing initiatives to increase awareness about organoids and growing incidence of NAFLD is expected to boost the market.
Break of primary participants was as mentioned below:
The key players in the global human liver models market are: Emulate (US), Ascendance Bio (US), HμREL (US), CN Bio (UK), Organovo (US), and Cyfuse Biomedical (Japan).
The report analyzes the human liver models market and aims at estimating the market size and future growth potential of this market based on various segments such as type and region. It provides detailed information regarding the major factors influencing the growth of this market and the regulatory analysis impacting market dynamics.
The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them garner a greater share. Firms purchasing the report could use one or any combination of the below mentioned three strategies.
This report provides insights into the following pointers: